ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND THEIR USES

AR135690A1Pending Publication Date: 2026-10-14ODYSSEY THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
ARP20250100942
Authority / Receiving Office
AR · AR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-27
Filing Date
2025-04-09
Publication Date
2026-10-14
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.

Claims

This application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind to tumor necrosis factor receptor 2 (TNFR2). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins and methods for treating a disease or disorder using the antigen-binding proteins.

1. An antigen-binding protein that specifically binds to the tumor necrosis factor receptor 2 (TNFR2), comprising a complementarity-determining region 3 (CDR3) comprising the amino acid sequence AADSDL(S / R)TV(V / T)VGPHDY (SEQ ID No. 61), A(A / G)(T / A / S)(P / L)(S / T)GKAY(T / S)Y (SEQ ID No. 4787), or (T / A / V)A(S / A)PTGRAF(T / N / A)Y (SEQ ID No. 66), wherein one or more non-alanine residues in the CDR3 sequence are optionally replaced with an alanine, and / or one or more alanine residues in the CDR3 sequence are optionally replaced with a glycine.

27. A fusion protein that specifically binds to the tumor necrosis factor receptor 2 (TNFR2), comprising one or more of said antigen-binding proteins of any of claims 1-26.

56. A conjugate comprising the antigen-binding protein of any of claims 1-26 or the fusion protein of any of claims 27-55, wherein the antigen-binding protein or the fusion protein is conjugated to a second residue.

61. A polynucleotide molecule encoding the antigen-binding protein of any of claims 1-26 or the fusion protein of any of claims 27-55.

62. A recombinant vector comprising the polynucleotide molecule of claim 61.

63. A host cell comprising the polynucleotide molecule of claim 61, or the recombinant vector of claim 62.